Cereno Scientific
5.72 SEK
-1.30 %
Less than 1K followers
CRNO B
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
Valuation
Income statement
Quarter data
Income statement
Financial statements, revenue, EBIT, valuation metrics, and quarterly estimates for Cereno Scientific
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| Revenue | 11.0 | ||||||
| growth-% | |||||||
| EBITDA | -13.1 | -15.7 | -15.0 | -27.5 | -44.6 | -75.6 | -73.8 |
| EBIT | -13.1 | -15.7 | -15.0 | -27.5 | -44.7 | -75.8 | -74.6 |
| Profit before taxes | -15.3 | -16.0 | -16.3 | -27.6 | -48.1 | -99.5 | -117.8 |
| Net income | -15.3 | -16.0 | -16.3 | -27.6 | -48.1 | -99.5 | -117.8 |
| EPS | -0.38 | -0.40 | -0.15 | -0.20 | -0.21 | -0.14 | -0.38 |
| Dividend | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Dividend ratio | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % | -0.0 % |
Profitability and return on capital
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|
| EBITDA-% | -119.2 % | ||||||
| EBIT-% | -119.2 % | ||||||
| ROE | -25.6 % | -16.1 % | -9.6 % | -13.7 % | -22.2 % | -51.9 % | -46.6 % |
| ROI | -23.9 % | -14.3 % | -9.0 % | -12.8 % | -16.9 % | -24.1 % | -29.2 % |